12:00 AM
Aug 12, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Astex Pharmaceuticals preclinical data

In a mouse xenograft model of melanoma with BRAF V600E mutations, AT13387 plus Zelboraf vemurafenib prevented tumor regrowth and delayed the emergence of resistant tumors compared to Zelboraf alone. Additionally, Astex said tumors that became resistant...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >